Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder
- PMID: 20036427
- DOI: 10.1016/j.psychres.2008.06.025
Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder
Abstract
Our objective was to explore the dose-response relationship in patients with panic disorder and social anxiety disorder comorbidity (DSM-IV). After 1 week of no-drug washout, 36 such patients were assigned to a double-blind controlled comparison of the effects of 30 mg and 60 mg of tranylcypromine, and were followed up for 12 weeks. The main instrument used to measure the number of panic attacks was the Sheehan Panic and Anticipatory Anxiety Scale. The primary outcome measure for social anxiety disorder symptoms was the mean change from baseline in the Liebowitz Social Anxiety Scale (LSAS). After 12 weeks of treatment, panic attacks were reduced 69.6% from baseline in the 30-mg group (n=19) compared with a 74.8% reduction in the 60-mg group (n=17). Twelve patients (70.6%) of the higher dose group and 14 patients (68.4%) of the lower dose were completely free of panic attacks. There was no difference in efficacy between the tranylcypromine groups in the panic disorder symptoms. The 60-mg dose was more efficacious as measured by the LSAS scores, showing a significant difference in relation to the lower group. Mean change from baseline in LSAS total score (mean+/-SD) for 30-mg group was 17.9+/-14.7 and for the 60-mg group was 35.0+/-14.8. The social anxiety symptom scale showed a two-fold greater change with the 60-mg dose, and the 30-mg dose group could be considered the equivalent of a placebo control group. Tranylcypromine--60 mg daily--was found effective in the treatment of panic disorder and social anxiety disorder comorbidity.
2008 Elsevier Ltd. All rights reserved.
Similar articles
-
Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.J Affect Disord. 2009 Jun;115(3):376-85. doi: 10.1016/j.jad.2008.10.005. Epub 2008 Nov 29. J Affect Disord. 2009. PMID: 19042026 Clinical Trial.
-
Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.Clin Ther. 2006 Feb;28(2):266-79. doi: 10.1016/j.clinthera.2006.02.011. Clin Ther. 2006. PMID: 16678648 Clinical Trial.
-
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.Depress Anxiety. 2009;26(3):212-21. doi: 10.1002/da.20549. Depress Anxiety. 2009. PMID: 19194995 Clinical Trial.
-
A review of 19 double-blind placebo-controlled studies in social anxiety disorder (social phobia).World J Biol Psychiatry. 2000 Jan;1(1):27-33. doi: 10.3109/15622970009150563. World J Biol Psychiatry. 2000. PMID: 12607230 Review.
-
Monoamine oxidase inhibitors in anxiety disorders.J Psychiatr Res. 1988;22 Suppl 1:87-98. doi: 10.1016/0022-3956(88)90070-2. J Psychiatr Res. 1988. PMID: 3050061 Review.
Cited by
-
Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.Focus (Am Psychiatr Publ). 2021 Jun;19(2):145-160. doi: 10.1176/appi.focus.20200048. Epub 2021 Jun 17. Focus (Am Psychiatr Publ). 2021. PMID: 34690578 Free PMC article.
-
Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018.Psychiatry Investig. 2019 Jan;16(1):50-58. doi: 10.30773/pi.2018.12.21.1. Epub 2019 Jan 25. Psychiatry Investig. 2019. PMID: 30696238 Free PMC article.
-
MAO-inhibitors in Parkinson's Disease.Exp Neurobiol. 2011 Mar;20(1):1-17. doi: 10.5607/en.2011.20.1.1. Epub 2011 Mar 31. Exp Neurobiol. 2011. PMID: 22110357 Free PMC article.
-
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.BMC Psychiatry. 2014;14 Suppl 1(Suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. BMC Psychiatry. 2014. PMID: 25081580 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical